Ionis holder plans Rule 144 sale of 6,179 shares

A holder of Ionis Pharmaceuticals common stock filed a notice of proposed sale of 6,179 shares under Rule 144.

Accepted by SEC EDGAR 01/30/2026 - 08:47 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

A holder of Ionis Pharmaceuticals common stock filed a notice of proposed sale of 6,179 shares under Rule 144. These shares have an aggregate market value of 512,271.93 and will be sold through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of 01/30/2026.

The securities were acquired as performance stock units granted under Ionis’ 2011 Equity Incentive Plan on 01/29/2026, with compensation as the form of payment. The notice also discloses a prior sale of 8,480 common shares on 01/16/2026 for gross proceeds of 636,932.80, and states that 161,137,930 common shares were outstanding.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Ionis Pharmaceuticals (IONS) Rule 144 filing disclose?

The filing discloses a planned Rule 144 sale of 6,179 Ionis common shares worth 512,271.93. The shares will be sold through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of January 30, 2026.

How were the 6,179 Ionis (IONS) shares in this Rule 144 filing acquired?

The 6,179 Ionis shares were acquired as PSUs granted under the company’s 2011 Equity Incentive Plan on January 29, 2026. The filing states the nature of payment as compensation, indicating the shares were earned rather than bought for cash.

What recent Ionis (IONS) share sales are reported in the past 3 months?

The document reports an earlier sale of 8,480 Ionis common shares on January 16, 2026 through Morgan Stanley Smith Barney, generating gross proceeds of 636,932.80. This transaction is disclosed alongside the newly planned sale of 6,179 shares.

How many Ionis Pharmaceuticals (IONS) shares are outstanding in this filing?

The notice states that 161,137,930 Ionis Pharmaceuticals common shares were outstanding. This figure provides context for the planned Rule 144 sale of 6,179 shares, helping investors gauge the relative size of the disclosed transactions.

Which broker and exchange are involved in the Ionis (IONS) Rule 144 sale?

The planned sale will be executed through Morgan Stanley Smith Barney, listed at 1585 Broadway, New York. The filing specifies that the Ionis common stock subject to the Rule 144 notice is to be sold on the NASDAQ securities exchange.

What representation does the selling holder make in the Ionis (IONS) Rule 144 notice?

By signing the notice, the selling holder represents they do not know any material adverse information about Ionis’ current or prospective operations that has not been publicly disclosed, consistent with Rule 144 and related insider trading safeguards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001970151
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IONIS PHARMACEUTICALS INC
SEC File Number	000-19125
Address of Issuer	2855 GAZELLE COURT CARLSBAD CALIFORNIA 92010
Phone	7609319200
Name of Person for Whose Account the Securities are To Be Sold	Birchler Brian
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	6179	512271.93	161137930	01/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/29/2026	PSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			6179	01/29/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Morgan Stanley Smith Barney 1585 Broadway New York CA 10036	Common Stock	01/16/2026	8480	636932.80

144: Remarks and Signature

Remarks
Date of Notice	01/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Brian Birchler
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)